Disc Medicine’s (IRON) Outperform Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Disc Medicine (NASDAQ:IRON) in a research note released on Tuesday morning,RTT News reports. They currently have a $90.00 target price on the stock, up from their previous target price of $83.00. Wedbush also issued estimates for Disc Medicine’s FY2026 earnings at ($3.96) EPS, FY2027 earnings at $2.64 EPS, FY2028 earnings at $7.51 EPS and FY2029 earnings at $12.05 EPS.

A number of other analysts have also commented on the company. Jefferies Financial Group initiated coverage on Disc Medicine in a research note on Wednesday, October 23rd. They issued a “buy” rating and a $89.00 price target for the company. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $66.00 to $110.00 in a research note on Monday, November 4th. Stifel Nicolaus increased their price target on shares of Disc Medicine from $79.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a research report on Monday, December 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research report on Tuesday, October 15th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Disc Medicine currently has an average rating of “Buy” and an average price target of $88.50.

Disc Medicine Trading Down 2.6 %

Shares of NASDAQ IRON opened at $56.99 on Tuesday. The stock’s 50-day moving average is $62.66 and its 200 day moving average is $53.72. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -14.32 and a beta of 0.75. Disc Medicine has a 1-year low of $25.60 and a 1-year high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.15. On average, analysts forecast that Disc Medicine will post -4.07 EPS for the current fiscal year.

Insider Activity

In related news, insider William Jacob Savage sold 14,183 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $65.45, for a total transaction of $928,277.35. Following the completion of the transaction, the insider now directly owns 40,405 shares in the company, valued at approximately $2,644,507.25. The trade was a 25.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director William Richard White sold 7,136 shares of Disc Medicine stock in a transaction on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The disclosure for this sale can be found here. Insiders have sold a total of 85,758 shares of company stock valued at $5,400,990 over the last ninety days. 4.24% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Disc Medicine

Several large investors have recently made changes to their positions in the company. Wellington Management Group LLP grew its position in Disc Medicine by 4.8% in the third quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock worth $90,429,000 after acquiring an additional 83,731 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in shares of Disc Medicine by 123.5% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock worth $79,090,000 after purchasing an additional 969,834 shares during the period. Deerfield Management Company L.P. Series C increased its position in shares of Disc Medicine by 53.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock valued at $46,119,000 after purchasing an additional 357,730 shares during the last quarter. Logos Global Management LP purchased a new stake in Disc Medicine during the 2nd quarter valued at $41,690,000. Finally, State Street Corp lifted its position in Disc Medicine by 39.7% in the third quarter. State Street Corp now owns 827,910 shares of the company’s stock worth $40,683,000 after buying an additional 235,115 shares during the last quarter. 83.70% of the stock is owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.